-
Mashup Score: 1Addressing Disparities and Improving Supportive Care in Hematopoietic Stem Cell Transplantation - 3 day(s) ago
Although scientific progress in HSCT is ongoing, gaps remain in both access to care and outcomes. An Education Session will review the latest research on overcoming disparities and managing psychosocial and symptom interventions.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Exploring Current Immunotherapy Treatment Approaches in Resectable Non–Small Cell Lung Cancer - 6 day(s) ago
With improved survival benefits with ICIs and targeted therapies in metastatic NSCLC, the use of these agents has made its way into early-stage NSCLC.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Improved survival benefits w/ ICIs & targeted therapies in metastatic #NSCLC have led to these agents being used in early-stage NSCLC. @OncBrothers, @ASridharMD, @ArpanAshokPatel & @IvyLorena_Md explore the current treatment landscape: https://t.co/9F5mB8KHSV #LCSM #ASCODailyNews https://t.co/HyimCZQ4vI
-
-
Mashup Score: 26
The Lancet Commission on Women, Power, and Cancer was created to address the overlapping forms of discrimination that women face in cancer prevention and treatment as patients, health professionals, researchers, policymakers, and unpaid caregivers. At an Education Session at the 2024 ASCO Annual Meeting will discuss how this theme applies to North America.
Source: dailynews.ascopubs.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 26
The Lancet Commission on Women, Power, and Cancer was created to address the overlapping forms of discrimination that women face in cancer prevention and treatment as patients, health professionals, researchers, policymakers, and unpaid caregivers. At an Education Session at the 2024 ASCO Annual Meeting will discuss how this theme applies to North America.
Source: dailynews.ascopubs.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 26
The Lancet Commission on Women, Power, and Cancer was created to address the overlapping forms of discrimination that women face in cancer prevention and treatment as patients, health professionals, researchers, policymakers, and unpaid caregivers. At an Education Session at the 2024 ASCO Annual Meeting will discuss how this theme applies to North America.
Source: dailynews.ascopubs.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 18To Provide Quality Cancer Care, Clinicians Must Appreciate the People Living With the Disease - 7 day(s) ago
An Education Session during ASCO24 will help oncologists foster deeper understanding of the needs of patients and caregivers, especially those from historically marginalized communities.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0New Collaborative Guideline Highlights the Importance of Multidisciplinary Care for Patients With Osteoradionecrosis - 8 day(s) ago
A joint International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer and ASCO guideline seeks to fill a gap in the clinical guidance for patients with head and neck cancers who develop osteoradionecrosis following their head and neck radiation.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 70Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ‘One Size Fit All’ or Is Customization Needed? - 8 day(s) ago
Enfortumab vedotin/pembrolizumab, gemcitabine-cisplatin/nivolumab, and the JAVELIN paradigm can all play a role as first-line therapy for appropriately selected patients with advanced urothelial carcinoma.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 123ctDNA Assays: Exploring Their Clinical Use in Oncology Care - 8 day(s) ago
ctDNA assays are quickly finding their way into the clinic. These assays have a potential role to play in all phases of the cancer continuum because they answer various clinical questions (Figure 1). Their use is moving up to earlier-stage settings from their initial development and approval for patients with metastatic cancer. As these agents enter more prominent clinical use, it is vital for clinicians to understand that there are different kinds of ctDNA assays.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Glecirasib Demonstrates Encouraging Efficacy and Safety in KRASG12C-Mutated NSCLC in Phase 2 Trial From China - 9 day(s) ago
Data from a single-arm phase 2 trial conducted in China showed that glecirasib produced a response rate of 48% in patients with advanced KRASG12C-mutated NSCLC when used in the second- or later-line setting.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
@khera_nandita @nmdp_org Read more about Dr. Khera's talk: https://t.co/1YEL2W6XuI Learn more about the #ACCESSInitiative: https://t.co/lIiR1TcauG